JAB 23E73
Alternative Names: JAB-23E73Latest Information Update: 02 Apr 2024
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer